Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

165.55
-0.1100-0.07%
Volume:2.36M
Turnover:392.41M
Market Cap:42.99B
PE:-11.64
High:167.10
Open:166.83
Low:165.13
Close:165.66
52wk High:176.60
52wk Low:133.73
Shares:259.67M
Float Shares:259.67M
Volume Ratio:1.30
T/O Rate:0.91%
Dividend:2.53
Dividend Rate:1.53%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.25
PE(LYR):-11.64

Loading ...

Xenon to Present at Wells Fargo Healthcare Conference

GlobeNewswire
·
Sep 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 04

Sector Update: Healthcare

MT Newswires Live
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Analysts’ Top Healthcare Picks: Dogwood Therapeutics (DWTX), Quoin Pharmaceuticals (QNRX)

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Health Care Roundup: Market Talk

Dow Jones
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)

TIPRANKS
·
Sep 03

Spire Healthcare grants Toscafund brief extension on potential 250p-per-share bid

TIPRANKS
·
Sep 03

Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)

TIPRANKS
·
Sep 03

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

TIPRANKS
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03